Protalix BioTherapeutics (PLX) Cash & Equivalents (2010 - 2026)

Protalix BioTherapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $711000.0 for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 96.35% year-over-year to $711000.0; the TTM figure through Mar 2026 stood at $711000.0 (down 96.35% YoY), while the FY2025 annual figure was $702000.0, down 96.45% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $711000.0, up from $702000.0 in the prior quarter.
• The five-year high for Cash & Equivalents was $48.2 million in Q2 2023, with the low at $702000.0 in Q4 2025.
• The 5-year median for Cash & Equivalents is $19.5 million (2025), against an average of $19.6 million.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents surged 285.72% in 2023, then plunged 96.45% in 2025.
• Protalix BioTherapeutics' Cash & Equivalents stood at $17.1 million in 2022, then soared by 38.12% to $23.6 million in 2023, then fell by 16.39% to $19.8 million in 2024, then slumped by 96.45% to $702000.0 in 2025, then rose by 1.28% to $711000.0 in 2026.
• Business Quant data shows PLX's Cash & Equivalents at $711000.0 in Q1 2026, $702000.0 in Q4 2025, and $13.6 million in Q3 2025.